Detection of polyomavirus bk reactivation after renal transplantation using an intensive decoy cell surveillance program is cost-effective

Transplantation

Volumn 92, Issue 9, 2011, Pages 1018-1023

  Chakera, Aron ^a   Dyar, Oliver James ^a   Hughes, Elizabeth ^b   Bennett, Sophia ^a   Hughes, David ^b   Roberts, Ian S D ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Decoy cell; Polyomavirus BK; Renal transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; BK VIRUS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECOY CELL SCREENING; FOLLOW UP; GRAFT REJECTION; HEALTH CARE COST; HEALTH SURVEY; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SCREENING; URINE CYTOLOGY; VIREMIA; VIRUS DETECTION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BK VIRUS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; CYTOLOGICAL TECHNIQUES; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; INFANT; KIDNEY TRANSPLANTATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TUMOR VIRUS INFECTIONS; URINE; YOUNG ADULT;

EID: 80055000788     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318230c09b     Document Type: Review

References (56)

1. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84 (Pt 6): 1499.
2. Comoli P, Hirsch HH, Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008; 13: 569.
3. Kean JM, Rao S, Wang M, et al. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5: e1000363.
4. Chesters PM, Heritage J, McCance DJ. Persistence of DNAsequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 1983; 147: 676.
5. Heritage J, Chesters PM, McCance DJ. The persistence of papovavirus BK DNA sequences in normal human renal tissue. J Med Virol 1981; 8: 143.
6. Zhong S, Zheng HY, Suzuki M, et al. Age-related urinary excretion of BK polyomavirus by nonimmunocompromised individuals. J Clin Microbiol 2007; 45: 193.
7. Lukacher AE, Moser JM, Hadley A, et al. Visualization of polyoma virus-specific CD8+ T cells in vivo during infection and tumor rejection. J Immunol 1999; 163: 3369.
8. Comoli P, Binggeli S, Ginevri F, et al. Polyomavirus-associated nephropathy: Update on BK virus-specific immunity. Transpl Infect Dis 2006; 8: 86.
9. HirschHH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
10. Babel N, Fendt J, Karaivanov S, et al. Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: Analysis of 4128 urine and serum samples. Transplantation 2009; 88: 89.
11. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019.
12. Funk GA, Gosert R, Comoli P, et al. Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant 2008; 8: 2368.
13. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145.
14. Vasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834.
15. Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 2009; 9: S1.
16. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with Tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
17. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3: 611.
18. Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727.
19. Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus- associated nephropathy. Am J Transplant 2010; 10: 2615.
20. Buehrig CK, Lager DJ, Stegall MD, et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64: 665.
21. Drachenberg CB, Papadimitriou JC, Wali R, et al. Improved outcome of polyoma virus allograft nephropathy with early biopsy. Transplant Proc 2004; 36: 758.
22. Wiseman AC. Polyomavirus nephropathy: A current perspective and clinical considerations. Am J Kidney Dis 2009; 54: 131.
23. Nickeleit V, Hirsch HH, Binet IF, et al. Polyomavirus infection of renal allograft recipients: From latent infection to manifest disease. J AmSoc Nephrol 1999; 10: 1080.
24. Stilmant MM, Freedlund MC, Schmitt GW. Cytologic evaluation of urine after kidney transplantation. Acta Cytol 1987; 31: 625.
25. Hoffman NG, Cook L, Atienza EE, et al. Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J Clin Microbiol 2008; 46: 2671.
26. Hirsch HH. Polyomavirus BK nephropathy: A (Re-)emerging complication in renal transplantation. Am J Transplant 2002; 2: 25.
27. Nickeleit V, Steiger J, Mihatsch MJ. Re: Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1. Transplantation 2003; 75: 2160.
28. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15: 324.
29. Thamboo TP, Jeffery KJM, Friend PJ, et al. Urine cytology screening for polyoma virus infection following renal transplantation: The Oxford experience. J Clin Pathol 2007; 60: 927.
30. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488.
31. Huang G, Chen LZ, Qiu J, et al. Prospective study of polyomavirus BK replication and nephropathy in renal transplant recipients in China: A single-center analysis of incidence, reduction in immunosuppression and clinical course. Clin Transplant 2010; 24: 599.
32. Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: A prospective evaluation. Transplantation 2007; 84: 323.
33. Wadei HM, Rule AD, Lewin M, et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirusassociated nephropathy (PVAN). Am J Transplant 2006; 6 (5 Pt 1): 1025.
34. Drachenberg C, Hirsch HH, Papadimitriou JC, et al. Cost efficiency in the prospective diagnosis and follow-up of polyomavirus allograft nephropathy. Transplant Proc 2004; 36: 3028.
35. Laskin BL, Goebel J. Cost-efficient screening for BK virus in pediatric kidney transplantation: A single-center experience and review of the literature. Pediatr Transplant 2010; 14: 589.
36. Cesaro S, Hirsch HH, Faraci M, et al. Cidofovir for BK virus-associated hemorrhagic cystitis: A retrospective study. Clin Infect Dis 2009; 49: 233.
37. Pallet N, Burgard M, Quamouss O, et al. Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation 2010; 89: 1542.
38. Smith JM, Jordan SC. Intravenous immunoglobulin as treatment for BK virus: Nephropathy. Pediatr Transplant 2009; 13: 11.
39. Teschner S, Gerke P, Geyer M, et al. Leflunomide therapy for polyomavirus- induced allograft nephropathy: Efficient BK virus elimination without increased risk of rejection. Transplant Proc 2009; 41: 2533.
40. Koukoulaki M, Apostolou T, Hadjiconstantinou V, et al. Impact of prophylactic administration of ciprofloxacin on BK polyoma virus replication. Transpl Infect Dis 2008; 10: 449.
41. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 2010; 11: 114.
42. Mannon RB. Polyomavirus nephropathy: What have we learned? Transplantation 2004; 77: 1313.
43. Gai M, Piccoli GB, Motta D, et al. Detecting 'decoy cells' by phasecontrast microscopy. Nephrol Dial Transplant 2004; 19: 1015.
44. Cheng XS, Bohl DL, Storch GA, et al. Inhibitory interactions between BK and JC virus among kidney transplant recipients. J Am Soc Nephrol 2011; 22: 825.
45. Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: Independent risk factors for BK virus replication. Transplantation 2008; 86: 521.
46. Kiberd BA. Screening to prevent polyoma virus nephropathy: A medical decision analysis. Am J Transplant 2005; 5: 2410.
47. Alméras C, Vetromile F, Garrigue V, et al. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis 2011; 13: 101.
48. Thakur R, Arora S, Nada R, et al. Prospective monitoring of BK virus reactivation in renal transplant recipients in North India. Transpl Infect Dis 2011; [Epub ahead of print. doi: 10.1111/j.1399-3062.2011.00634.x.
49. Geramizadeh B, Roozbeh J, Malek-Hosseini SA, et al. Urine cytology as a useful screening method for polyoma virus nephropathy in renal transplant patients: A single-center experience. Transplant Proc 2006; 38: 2923.
50. Saundh BK, Tibble S, Baker R, et al. Different patterns of BK and JC polyomavirus reactivation following renal transplantation. J Clin Pathol 2010; 63: 714.
51. Mylonakis E, Goes N, Rubin RH, et al. BK virus in solid organ transplant recipients: An emerging syndrome. Transplantation 2001; 72: 1587.
52. Pérez-Torres D, Bertrán-Pasarell J, Santiago-Delpín E, et al. Factors and outcome in BK virus nephropathy in a Hispanic kidney transplant population. Transpl Infect Dis 2010; 12: 16.
53. Wilson J, Junger G. Principles and practice of screening for disease. Geneva: WHO 1968 (publication No. 34)
54. Wilson JM. Principles of screening for disease. Proc R Soc Med 1971; 64: 1255.
55. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003; 57: 93.
56. Sampson VB, Dunn SP, Rymeski B, et al. Failure of immunosuppressive drug levels to predict T-cell reactivity in pediatric transplant patients. J Pediatr Surg 2008; 43: 1134.